Login / Signup

Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis.

Cheng ChenMichael P DouglasMeera V RagavanKathryn A PhillipsJeroen P Jansen
Published in: Molecular diagnosis & therapy (2024)
ctDNA testing demonstrated an overall acceptable diagnostic accuracy in patients with aNSCLC, however, sensitivity varied greatly by driver mutation. Further research is needed, especially for uncommon driver mutations, to better understand the CU of ctDNA testing in guiding targeted treatments for aNSCLC.
Keyphrases
  • circulating tumor
  • advanced non small cell lung cancer
  • cell free
  • circulating tumor cells
  • epidermal growth factor receptor
  • cancer therapy
  • drug delivery